VectivBio
Comet Therapeutics (formerly TM3) was founded in April 2017 in The Netherlands. The company focused on the treatment of orphan neurological disorders through Coenzyme-A substitution therapy strategies.
In 2021, VectivBio Holding AG (VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, acquired Comet Therapeutics, significantly expanding VectivBio’s rare disease pipeline.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Exit
Website
vectivbio.com
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.